DRUG · Unmapped registry intervention
VX-509
Find medicine records ·
Find other trials using this name
Clinical trial
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
NCT01754935
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
VX-509 matching placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
VX-509DRUG
Sponsors & collaborators
Vertex Pharmaceuticals Incorporatedlead sponsor
Mapped research locations
San AntonioTexas, United States1SeattleWashington, United States1RochesterNew York, United States1CharlestonSouth Carolina, United States1MemphisTennessee, United States1Kansas CityKansas, United States1SpokaneWashington, United States1Fort LauderdaleFlorida, United States1StanfordCalifornia, United States1DecaturGeorgia, United States1West Palm BeachFlorida, United States1LincolnNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01754935 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.